Barry McLean, MD
Internal Medicine · Homewood, ALNPI 1588634679
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $21,243 of the $24,492 with a category attached, or 86.7%. It is spread thinly across 48 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $4,403 and has fallen 68.0% since, to $1,408 in 2025. Among internal medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,361 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Roche Products Limited$2K
- Lilly USA, LLC$2K
- AbbVie$2K
- Pfizer$1K
- Johnson & Johnson$1K
- plus $13K from 42 others
Across 406 payments — averaging $9893.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.4M
- Bavarian Nordic A/s$1.3M
- Novartis$446K
- Pfizer$348K
- Acella Pharmaceuticals, LLC$161K
- Novo Nordisk AS$152K
- plus $175K from 11 others
What the payments were for
- Consulting fees$2,43010%
- Speaking & faculty fees$8003%
- Food & beverage$21,24387%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xofluza$2,430
- NEXLIZET$800
- NEXLETOL$800
- Ozempic$352
- Vascepa$141
- Saxenda$124
- DEXCOM G7 GSS (161)$120
- STEGLATRO$104
- Xultophy 100/3.6$103
How this compares
$24,492 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 223 | $276,701 |
| OzempicSemaglutide | 132 | $124,666 |
| EliquisApixaban | 132 | $110,960 |
| JardianceEmpagliflozin | 83 | $79,319 |
| KerendiaFinerenone | 70 | $52,628 |
| JanuviaSitagliptin Phosphate | 28 | $33,086 |
| EntrestoSacubitril/Valsartan | 36 | $31,549 |
| FarxigaDapagliflozin Propanediol | 28 | $30,310 |
| ProliaDenosumab | 15 | $25,968 |
| Repatha SureclickEvolocumab | 32 | $25,341 |
| MyrbetriqMirabegron | 37 | $23,977 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $22,564 |
| LinzessLinaclotide | 29 | $21,104 |
| XareltoRivaroxaban | 25 | $20,724 |
| TrulicityDulaglutide | 18 | $17,923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,818 | $294,625241 claims |
| Novo NordiskOzempic | $2,950 | $124,666132 claims |
| PfizerEliquis | $1,287 | $110,960132 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $449 | $107,866116 claims |
| MerckJanuvia, Janumet, Lagevrio (Eua) | $490 | $56,95850 claims |
| BayerKerendia | $1,167 | $52,62870 claims |
| NovartisEntresto | $467 | $31,54936 claims |
| AstraZenecaFarxiga | $1,195 | $30,31028 claims |
| AmgenProlia | $975 | $25,96815 claims |
| Astellas Pharma US IncMyrbetriq | $358 | $23,97737 claims |
| AbbVieLinzess | $1,505 | $21,10429 claims |
| Johnson & JohnsonXarelto | $1,281 | $20,72425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Homewood
- Ryan WeldonBirmingham$458K
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Robert LewisBirmingham$187K
- Rosalind BowlesGadsden$168K
- Sonja PettusJasper$117K
- Bobby WrightsMobile$89K
- Thomas HuddleBirmingham$76K
- Rahel AzizMobile$67K
- Justin HoveyDothan$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.